ctDNA-Guided Adjuvant Therapy in Stage III Colon Cancer: Prognostic Validation but No Benefit from Chemotherapy Intensification — Key Findings from the DYNAMIC-III Randomized Phase 2/3 Trial
Posted innews Oncology Pathology & Lab Medicine

ctDNA-Guided Adjuvant Therapy in Stage III Colon Cancer: Prognostic Validation but No Benefit from Chemotherapy Intensification — Key Findings from the DYNAMIC-III Randomized Phase 2/3 Trial

The DYNAMIC-III trial validates circulating tumor DNA (ctDNA) as a strong prognostic marker in stage III colon cancer. ctDNA-guided de-escalation reduced oxaliplatin exposure and hospitalizations with near-standard outcomes, but escalation for ctDNA-positive patients failed to improve recurrence-free survival.
Dual TIGIT and PD‑1 Blockade with Domvanalimab + Zimberelimab plus FOLFOX Shows Promising Activity in First‑Line Advanced HER2‑Negative Gastroesophageal Adenocarcinoma
Posted innews Oncology

Dual TIGIT and PD‑1 Blockade with Domvanalimab + Zimberelimab plus FOLFOX Shows Promising Activity in First‑Line Advanced HER2‑Negative Gastroesophageal Adenocarcinoma

In a phase 2 cohort (EDGE‑Gastric A1), domvanalimab (anti‑TIGIT) plus zimberelimab (anti‑PD‑1) combined with FOLFOX produced a 59% ORR, median PFS 12.9 months and median OS 26.7 months in 41 previously untreated HER2‑negative gastroesophageal adenocarcinoma patients, with immune‑related AEs in 27%.
A 21‑Valent Adult Pneumococcal Conjugate Vaccine (V116) Is Immunogenic and Well Tolerated in People Living with HIV: Results from STRIDE‑7
Posted inHIV/AIDS Infectious Diseases news

A 21‑Valent Adult Pneumococcal Conjugate Vaccine (V116) Is Immunogenic and Well Tolerated in People Living with HIV: Results from STRIDE‑7

In STRIDE‑7, the adult‑specific 21‑valent conjugate vaccine V116 produced robust opsonophagocytic responses across all 21 serotypes and had a favorable tolerability profile in adults living with HIV, supporting broader serotype coverage compared with currently licensed vaccines.
Perioperative Pembrolizumab + Trastuzumab with FLOT Achieves High pCR and Feasible Safety in HER2‑Positive Localized Esophagogastric Adenocarcinoma: Interim PHERFLOT Results
Posted inGeneral Surgery news Oncology

Perioperative Pembrolizumab + Trastuzumab with FLOT Achieves High pCR and Feasible Safety in HER2‑Positive Localized Esophagogastric Adenocarcinoma: Interim PHERFLOT Results

Interim results from the phase 2 PHERFLOT trial show a 48.4% pathological complete response and a 67.7% major pathologic response after four cycles of pembrolizumab, trastuzumab and FLOT in localized HER2‑positive esophagogastric adenocarcinoma; safety was consistent with known profiles.
MAGNITUDE final analyses: Niraparib + Abiraterone improves symptoms and delays chemotherapy but not overall survival in HRR‑altered mCRPC
Posted innews Oncology Urology

MAGNITUDE final analyses: Niraparib + Abiraterone improves symptoms and delays chemotherapy but not overall survival in HRR‑altered mCRPC

Final MAGNITUDE results show niraparib combined with abiraterone–prednisone improves radiographic PFS, time to symptomatic progression and delays cytotoxic chemotherapy in HRR‑altered mCRPC (notably BRCA1/2), preserves patient‑reported quality of life, but did not demonstrate a statistically significant overall survival benefit in the primary analysis.
Neoadjuvant Nivolumab With or Without Low‑Dose Ipilimumab Produces High Pathologic Response and Organ Preservation in Resectable Cutaneous Squamous Cell Carcinoma: Results from the MATISSE Phase 2 Trial
Posted inDermatology news Oncology

Neoadjuvant Nivolumab With or Without Low‑Dose Ipilimumab Produces High Pathologic Response and Organ Preservation in Resectable Cutaneous Squamous Cell Carcinoma: Results from the MATISSE Phase 2 Trial

The randomized MATISSE trial shows neoadjuvant nivolumab ± low‑dose ipilimumab yields high major/partial pathological response rates, excellent 2‑year disease‑specific survival, and enables organ preservation in many patients with resectable cutaneous squamous cell carcinoma.